- Adalimumab, sold
under the
brand name
Humira and others, is a disease-modifying
antirheumatic drug and
monoclonal antibody used to
treat rheumatoid arthritis...
- company's seat in
Forbes Global 2000 was 74. The company's
primary product is
Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered...
-
discussions regarding the
applicability of the
royalty offset provisions for
Humira" (Adalimumab) with
Abbott Laboratories in the High
Court of London. In December...
-
Humira Saqib (born 1980) is an
Afghan journalist and women's
human rights activist.
Through her
writings in the
magazine Negah-e-Zan (A
Vision of Women)...
-
antitrust implications. In In re
Humira, 465 F.Supp.3d 811 (N.D. Ill. 2020), a
class of third-party
payors for
Humira argued that
pharmaceutical company...
- (PDF) from the
original on
September 19, 2020.
Retrieved June 9, 2020. "
Humira EPAR".
European Medicines Agency (EMA).
Archived from the
original on February...
-
successful was
HUMIRA (adalimumab),
discovered by
Cambridge Antibody Technology as D2E7 and
developed and
marketed by
Abbott Laboratories.
HUMIRA, an antibody...
-
Abbott Laboratories over the
development and sale of the
arthritis drug
Humira,
claiming Abbott used
technology licensed exclusively to
Johnson & Johnson's...
-
antibody such as
infliximab (Remicade)
binding directly to TNF,
adalimumab (
Humira),
certolizumab pegol (Cimzia) or with a
decoy circulating receptor fusion...
- Switzerland. In July 2023,
Sandoz launched a
biosimilar version of
AbbVie Inc's
Humira,
under the label, Hyrimoz. In
September 2023,
Novartis announced that the...
